Ocular gene therapy for neovascular AMD: a new era? – Authors' reply

Peter A. Campochiaro; Jeffrey S. Heier; Saleema Kherani; Annaig Le-Halpere; Abraham Scaria

doi:10.1016/S0140-6736(17)32424-8

Ocular gene therapy for neovascular AMD: a new era? – Authors' reply

Peter A. Campochiaro, Jeffrey S. Heier, Saleema Kherani, Annaig Le-Halpere, Abraham Scaria

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	2140
Number of pages	1
Journal	The Lancet
Volume	390
Issue number	10108
DOIs	https://doi.org/10.1016/S0140-6736(17)32424-8
State	Published - Nov 11 2017

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(17)32424-8

Cite this

@article{ee75442c38a145bf92150ddc40043876,

title = "Ocular gene therapy for neovascular AMD: a new era? – Authors' reply",

author = "Campochiaro, {Peter A.} and Heier, {Jeffrey S.} and Saleema Kherani and Annaig Le-Halpere and Abraham Scaria",

note = "Funding Information: PAC reports grants and personal fees from Alimera, Allergan, AsclipiX, Rxi, Regenexbio, Aerpio, Genentech/Roche; grants from Abbvie, GlaxoSmithKline, Oxford BioMedica, Regeneron; and personal fees from Applied Genetic Technologies, Allegro, Intrexon, Merck, Novartis, and Bayer, outside of the submitted work. JSH and PAC report grants from Genzyme during the conduct of the study. JSH reports grants and personal fees from Acucela, Daiichi, Eyegate Pharmaceuticals, Genentech/Roche, Janssen R&D, Ocudyne, Regeneron, SciFluor Life Sciences; personal fees from Adverum, Aerie, Aerpio Therapeutics, Alcon, Allegro Ophthalmics, Allergan, Kala Pharmaceuticals, Kanghong, Notal Vision, Regenxbio, RetroSense, Stealth Biotherapeutics, Valeant Pharmaceuticals, Voyager Therapeutics; grants from Apellis, Astellas, Bayer, Corcept, Genzyme, LPath, Neurotech, Novartis, Ophthotech, Thrombogenics, Tyrogenex; and other from Ocular Therapeutics, outside of the submitted work. AL-H and AS are current employees of Sanofi Genzyme. AS has two patents issued (US 7928072, US 8658602). SK declares no competing interests.",

year = "2017",

month = nov,

day = "11",

doi = "10.1016/S0140-6736(17)32424-8",

language = "English (US)",

volume = "390",

pages = "2140",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10108",

}

TY - JOUR

T1 - Ocular gene therapy for neovascular AMD

T2 - a new era? – Authors' reply

AU - Campochiaro, Peter A.

AU - Heier, Jeffrey S.

AU - Kherani, Saleema

AU - Le-Halpere, Annaig

AU - Scaria, Abraham

N1 - Funding Information: PAC reports grants and personal fees from Alimera, Allergan, AsclipiX, Rxi, Regenexbio, Aerpio, Genentech/Roche; grants from Abbvie, GlaxoSmithKline, Oxford BioMedica, Regeneron; and personal fees from Applied Genetic Technologies, Allegro, Intrexon, Merck, Novartis, and Bayer, outside of the submitted work. JSH and PAC report grants from Genzyme during the conduct of the study. JSH reports grants and personal fees from Acucela, Daiichi, Eyegate Pharmaceuticals, Genentech/Roche, Janssen R&D, Ocudyne, Regeneron, SciFluor Life Sciences; personal fees from Adverum, Aerie, Aerpio Therapeutics, Alcon, Allegro Ophthalmics, Allergan, Kala Pharmaceuticals, Kanghong, Notal Vision, Regenxbio, RetroSense, Stealth Biotherapeutics, Valeant Pharmaceuticals, Voyager Therapeutics; grants from Apellis, Astellas, Bayer, Corcept, Genzyme, LPath, Neurotech, Novartis, Ophthotech, Thrombogenics, Tyrogenex; and other from Ocular Therapeutics, outside of the submitted work. AL-H and AS are current employees of Sanofi Genzyme. AS has two patents issued (US 7928072, US 8658602). SK declares no competing interests.

PY - 2017/11/11

Y1 - 2017/11/11

UR - http://www.scopus.com/inward/record.url?scp=85032894975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032894975&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)32424-8

DO - 10.1016/S0140-6736(17)32424-8

M3 - Letter

C2 - 29143750

AN - SCOPUS:85032894975

VL - 390

SP - 2140

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10108

ER -

Ocular gene therapy for neovascular AMD: a new era? – Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this